Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Enobosarm

Stage Phase 2Stale

Sponsor Veru Inc

Route oral and injection

Class SARM

Mechanism oral selective androgen receptor modulator

Sources

registry, as of 2026-09-04Stale

https://clinicaltrials.gov/study/NCT07446998

Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE2. Lead sponsor Veru Inc.. Enrollment 239. Conditions Obesity & Overweight; Mobility Disability; HOMA-IR. The primary objective of this study is to assess the effect of enobosarm on total body weight

ClinicalTrials.gov NCT07446998 protocol and results modules

registry, as of 2025-09-17Stale

https://clinicaltrials.gov/study/NCT06282458

Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt. Overall status COMPLETED. Phases PHASE2. Lead sponsor Veru Inc.. Enrollment 168. Conditions Muscle Loss; Obesity. The primary objective of this study is to assess the effect of enobosarm on total lean mass as measured by DEXA in patients maintained on GLP-1 receptor agonists.

ClinicalTrials.gov NCT06282458 protocol and results modules

publication, as of 2024-03-04Stale

https://pubmed.ncbi.nlm.nih.gov/38342115/

suppressor in oestrogen receptor-positive breast cancer. The activity and safety of enobosarm, an oral selective androgen receptor modulator, was evaluated in women with oestrogen receptor (ER)-positive, HER2-negative, and androgen receptor (AR)-positive disease. Women who were postmenopausal (aged ≥18 years) wi

PMID 38342115

Studies

PLATEAU

Registry NCT07446998

Phase Phase 2

Status Active, not recruiting

Enrollment 239

Start 2026-03-26

Subcutaneous injectable semaglutide and oral enobosarm 3mg

Dose 3mg

Regimen weekly

Comparator placebo

Population Obesity & Overweight; Mobility Disability; HOMA-IR

Subcutaneous injectable semaglutide and oral Placebo

Regimen weekly

Population Obesity & Overweight; Mobility Disability; HOMA-IR

QUALITY

Registry NCT06282458

Phase Phase 2

Status Completed

Enrollment 168

Start 2024-04-29

Primary completion 2025-04-11

Study completion 2025-08-22

Catalyst Primary completion. 2025-04-11. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Semaglutide and Enobosarm 3 mg QD by mouth (E3G) daily

Dose 3 mg

Regimen once weekly

Weeks 1

Comparator placebo

Population Muscle Loss; Obesity

Semaglutide and Enobosarm 6 mg QD by mouth (E6G) daily

Dose 6 mg

Regimen once weekly

Weeks 1

Comparator placebo

Population Muscle Loss; Obesity

GLP-1 receptor agonist and Placebo QD by mouth (PG) daily

Regimen once weekly

Weeks 1

Population Muscle Loss; Obesity